NKTR Stock Overview
A biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Nektar Therapeutics Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.94 |
| 52 Week High | US$1.93 |
| 52 Week Low | US$0.48 |
| Beta | 0.56 |
| 1 Month Change | -17.19% |
| 3 Month Change | -27.38% |
| 1 Year Change | 67.08% |
| 3 Year Change | -93.09% |
| 5 Year Change | -95.50% |
| Change since IPO | -74.83% |
Recent News & Updates
Recent updates
Why Investors Shouldn't Be Surprised By Nektar Therapeutics' (NASDAQ:NKTR) 27% Share Price Plunge
Dec 06
Investor Optimism Abounds Nektar Therapeutics (NASDAQ:NKTR) But Growth Is Lacking
Oct 18Some Nektar Therapeutics (NASDAQ:NKTR) Shareholders Look For Exit As Shares Take 35% Pounding
Jun 19There's No Escaping Nektar Therapeutics' (NASDAQ:NKTR) Muted Revenues Despite A 44% Share Price Rise
Feb 15Nektar Therapeutics' (NASDAQ:NKTR) Business And Shares Still Trailing The Industry
Dec 31Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?
Nov 06Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?
Apr 24Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely
Jan 24Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?
Aug 19Nektar: Time To Abandon Ship
Jul 17Nektar promotes internal executive to CFO role
Jul 01We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully
May 11Shareholder Returns
| NKTR | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 4.8% | -1.9% | -1.1% |
| 1Y | 67.1% | 6.5% | 22.4% |
Return vs Industry: NKTR exceeded the US Pharmaceuticals industry which returned 7.9% over the past year.
Return vs Market: NKTR exceeded the US Market which returned 23.7% over the past year.
Price Volatility
| NKTR volatility | |
|---|---|
| NKTR Average Weekly Movement | 8.5% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NKTR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NKTR's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 137 | Howard Robin | www.nektar.com |
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system’s natural ability to fight cancer. The company serves its clients in the United States and internationally.
Nektar Therapeutics Fundamentals Summary
| NKTR fundamental statistics | |
|---|---|
| Market cap | US$175.09m |
| Earnings (TTM) | -US$168.30m |
| Revenue (TTM) | US$93.14m |
1.9x
P/S Ratio-1.0x
P/E RatioIs NKTR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NKTR income statement (TTM) | |
|---|---|
| Revenue | US$93.14m |
| Cost of Revenue | US$29.99m |
| Gross Profit | US$63.15m |
| Other Expenses | US$231.45m |
| Earnings | -US$168.30m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.91 |
| Gross Margin | 67.80% |
| Net Profit Margin | -180.70% |
| Debt/Equity Ratio | 200.1% |
How did NKTR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 11:02 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nektar Therapeutics is covered by 34 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Difei Yang | Aegis Capital Corporation |
| Richard Silver | Barclays |
| Aydin Huseynov | Benchmark Company |